Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 8/2017

12.08.2017 | ORIGINAL ARTICLE

Synchronous colorectal liver metastases: focus on the elderly

An Effectiveness Study from Routine Care

verfasst von: Markus Albertsmeier, Andrea Engel, Markus O. Guba, Sebastian Stintzing, Tobias S. Schiergens, Gabriele Schubert-Fritschle, Dieter Hölzel, Jens Werner, Martin K. Angele, Jutta Engel

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The goal of this study was to analyze the use and the effectiveness of both surgery and different chemotherapies in patients with synchronous colorectal liver metastases (CLMs) ≥70 years compared to younger patients.

Methods

Survival was analyzed in 456 patients (24.3% ≥70 years) treated for CLM in a single center using Kaplan-Meier estimation of overall survival (OS), calculation of relative survival as estimate for disease-specific survival, and a Cox regression model.

Results

Complete surgical resections were achieved more often in patients aged <70 years (39.2 vs. 28.1%, P = 0.056), and young patients more frequently received irinotecan or platin-based chemotherapies (70.3 vs. 41.6%, P < 0.001). Three-year OS and relative survival of patients ≥70 years were significantly lower compared to younger patients (OS 34.3 vs. 43.5%, P = 0.0114). In a Cox regression model, complete surgical removal of liver metastases was the most effective treatment (HR 0.313, P < 0.001) followed by chemotherapy (irinotecan/platin-based: HR 0.371, 5-FU only: HR 0.673, P < 0.001). Having >5 liver metastases, the presence of extrahepatic metastases, high grading, and a nodal positive primary but not age ≥70 years were associated with an increased risk of death.

Conclusions

Our data support radical resection and highly effective chemotherapy in selected elderly patients with CLM.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Adam R, Frilling A, Elias D et al (2010) Liver resection of colorectal metastases in elderly patients. Br J Surg 97:366–376CrossRefPubMed Adam R, Frilling A, Elias D et al (2010) Liver resection of colorectal metastases in elderly patients. Br J Surg 97:366–376CrossRefPubMed
2.
Zurück zum Zitat Anderson J, Cain K, Gelber R (1983) Analysis of survival by tumor response. J Clin Oncol 1:710–719CrossRefPubMed Anderson J, Cain K, Gelber R (1983) Analysis of survival by tumor response. J Clin Oncol 1:710–719CrossRefPubMed
3.
Zurück zum Zitat Baltatzis M, Chan AKC, Jegatheeswaran S et al (2016) Colorectal cancer with synchronous hepatic metastases: systematic review of reports comparing synchronous surgery with sequential bowel-first or liver-first approaches. Eur J Surg Oncol 42:159–165CrossRefPubMed Baltatzis M, Chan AKC, Jegatheeswaran S et al (2016) Colorectal cancer with synchronous hepatic metastases: systematic review of reports comparing synchronous surgery with sequential bowel-first or liver-first approaches. Eur J Surg Oncol 42:159–165CrossRefPubMed
4.
Zurück zum Zitat Booth CM, Nanji S, Wei X et al (2015) Management and outcome of colorectal cancer liver metastases in elderly patients: a population-based study. JAMA Oncol 1:1111–1119CrossRefPubMed Booth CM, Nanji S, Wei X et al (2015) Management and outcome of colorectal cancer liver metastases in elderly patients: a population-based study. JAMA Oncol 1:1111–1119CrossRefPubMed
5.
Zurück zum Zitat Cannon RM, Martin RC, Callender GG et al (2011) Safety and efficacy of hepatectomy for colorectal metastases in the elderly. J Surg Oncol 104:804–808CrossRefPubMed Cannon RM, Martin RC, Callender GG et al (2011) Safety and efficacy of hepatectomy for colorectal metastases in the elderly. J Surg Oncol 104:804–808CrossRefPubMed
6.
Zurück zum Zitat Chau I, Norman AR, Cunningham D et al (2004) Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 91:1453–1458CrossRefPubMedPubMedCentral Chau I, Norman AR, Cunningham D et al (2004) Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 91:1453–1458CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Colorectal Cancer Collaborative Group (2000) Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 356:968–974CrossRef Colorectal Cancer Collaborative Group (2000) Surgery for colorectal cancer in elderly patients: a systematic review. Lancet 356:968–974CrossRef
8.
Zurück zum Zitat Cook EJ, Welsh FKS, Chandrakumaran K et al (2012) Resection of colorectal liver metastases in the elderly: does age matter? Color Dis 14:1210–1216CrossRef Cook EJ, Welsh FKS, Chandrakumaran K et al (2012) Resection of colorectal liver metastases in the elderly: does age matter? Color Dis 14:1210–1216CrossRef
9.
Zurück zum Zitat Ederer F, Heise H (1959) Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10, end results evaluation section. National Cancer Institute, Bethesda Ederer F, Heise H (1959) Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10, end results evaluation section. National Cancer Institute, Bethesda
10.
Zurück zum Zitat Ferlay J, Soerjomataram I, Ervik M et al (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11. International Agency for Research on Cancer, Lyon Ferlay J, Soerjomataram I, Ervik M et al (2013) GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase no. 11. International Agency for Research on Cancer, Lyon
11.
Zurück zum Zitat Figueras J, Ramos E, López-Ben S et al (2007) Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile? Clin Transl Oncol 9:392–400CrossRefPubMed Figueras J, Ramos E, López-Ben S et al (2007) Surgical treatment of liver metastases from colorectal carcinoma in elderly patients. When is it worthwhile? Clin Transl Oncol 9:392–400CrossRefPubMed
12.
Zurück zum Zitat Folprecht G, Cunningham D, Ross P et al (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15:1330–1338CrossRefPubMed Folprecht G, Cunningham D, Ross P et al (2004) Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 15:1330–1338CrossRefPubMed
13.
Zurück zum Zitat Folprecht G, Seymour MT, Saltz L et al (2008) Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26:1443–1451CrossRefPubMed Folprecht G, Seymour MT, Saltz L et al (2008) Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26:1443–1451CrossRefPubMed
14.
Zurück zum Zitat Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318 discussion 318-321 CrossRefPubMedPubMedCentral Fong Y, Fortner J, Sun RL et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318 discussion 318-321 CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMed Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMed
16.
Zurück zum Zitat Goldberg RM, Tabah-Fisch I, Bleiberg H et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085–4091CrossRefPubMed Goldberg RM, Tabah-Fisch I, Bleiberg H et al (2006) Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24:4085–4091CrossRefPubMed
17.
Zurück zum Zitat Gramont AD, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947CrossRefPubMed Gramont AD, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947CrossRefPubMed
18.
Zurück zum Zitat Hackl C, Neumann P, Gerken M et al (2014) Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 14:810CrossRefPubMedPubMedCentral Hackl C, Neumann P, Gerken M et al (2014) Treatment of colorectal liver metastases in Germany: a ten-year population-based analysis of 5772 cases of primary colorectal adenocarcinoma. BMC Cancer 14:810CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Hölzel D, Engel J (2012) Klinische Krebsregister: Auf Erfahrungen aus dem Alltag kann nicht verzichtet werden. Dtsch Arztebl Int 109:424–425 Hölzel D, Engel J (2012) Klinische Krebsregister: Auf Erfahrungen aus dem Alltag kann nicht verzichtet werden. Dtsch Arztebl Int 109:424–425
20.
Zurück zum Zitat Jackson NA, Barrueco J, Soufi-Mahjoubi R et al (2009) Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 115:2617–2629CrossRefPubMed Jackson NA, Barrueco J, Soufi-Mahjoubi R et al (2009) Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer 115:2617–2629CrossRefPubMed
21.
Zurück zum Zitat Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683CrossRefPubMedPubMedCentral Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27:3677–3683CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Kulik U, Framke T, Großhennig A et al (2011) Liver resection of colorectal liver metastases in elderly patients. World J Surg 35:2063CrossRefPubMed Kulik U, Framke T, Großhennig A et al (2011) Liver resection of colorectal liver metastases in elderly patients. World J Surg 35:2063CrossRefPubMed
23.
Zurück zum Zitat Leporrier J, Maurel J, Chiche L et al (2006) A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 93:465–474CrossRefPubMed Leporrier J, Maurel J, Chiche L et al (2006) A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg 93:465–474CrossRefPubMed
24.
25.
Zurück zum Zitat Mitry E, Douillard JY, Van Cutsem E et al (2004) Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 15:1013–1017CrossRefPubMed Mitry E, Douillard JY, Van Cutsem E et al (2004) Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 15:1013–1017CrossRefPubMed
26.
Zurück zum Zitat Nagano Y, Nojiri K, Matsuo K et al (2005) The impact of advanced age on hepatic resection of colorectal liver metastases. J Am Coll Surg 201:511–516CrossRefPubMed Nagano Y, Nojiri K, Matsuo K et al (2005) The impact of advanced age on hepatic resection of colorectal liver metastases. J Am Coll Surg 201:511–516CrossRefPubMed
27.
Zurück zum Zitat Neumann UP, Seehofer D, Neuhaus P (2010) The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Arztebl Int 107:335–342PubMedPubMedCentral Neumann UP, Seehofer D, Neuhaus P (2010) The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Arztebl Int 107:335–342PubMedPubMedCentral
28.
Zurück zum Zitat Noren A, Eriksson HG, Olsson LI (2016) Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study. Eur J Cancer 53:105–114CrossRefPubMed Noren A, Eriksson HG, Olsson LI (2016) Selection for surgery and survival of synchronous colorectal liver metastases; a nationwide study. Eur J Cancer 53:105–114CrossRefPubMed
29.
Zurück zum Zitat Obeidat NA, Pradel FG, Zuckerman IH et al (2009) Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer. Am J Geriatr Pharmacother 7:343–354CrossRefPubMed Obeidat NA, Pradel FG, Zuckerman IH et al (2009) Outcomes of irinotecan-based chemotherapy regimens in elderly Medicare patients with metastatic colorectal cancer. Am J Geriatr Pharmacother 7:343–354CrossRefPubMed
30.
Zurück zum Zitat Office for National Statistics (2013) Statistical bulletin: cancer survival in England: patients diagnosed 2007–2011 and followed up to 2012. Office for National Statistics, Newport Office for National Statistics (2013) Statistical bulletin: cancer survival in England: patients diagnosed 2007–2011 and followed up to 2012. Office for National Statistics, Newport
31.
Zurück zum Zitat Phan K, An VV, Ha H et al (2015) Hepatic resection for malignant liver tumours in the elderly: a systematic review and meta-analysis. ANZ J Surg 85:815–822CrossRefPubMed Phan K, An VV, Ha H et al (2015) Hepatic resection for malignant liver tumours in the elderly: a systematic review and meta-analysis. ANZ J Surg 85:815–822CrossRefPubMed
32.
Zurück zum Zitat Potosky AL, Harlan LC, Kaplan RS et al (2002) Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20:1192–1202CrossRefPubMed Potosky AL, Harlan LC, Kaplan RS et al (2002) Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20:1192–1202CrossRefPubMed
33.
Zurück zum Zitat Power DG, Lichtman SM (2010) Chemotherapy for the elderly patient with colorectal cancer. Cancer J 16:241–252CrossRefPubMed Power DG, Lichtman SM (2010) Chemotherapy for the elderly patient with colorectal cancer. Cancer J 16:241–252CrossRefPubMed
34.
Zurück zum Zitat Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059–2069CrossRefPubMed Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059–2069CrossRefPubMed
35.
Zurück zum Zitat Sargent DJ, Goldberg RM, Jacobson SD et al (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097CrossRefPubMed Sargent DJ, Goldberg RM, Jacobson SD et al (2001) A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 345:1091–1097CrossRefPubMed
36.
Zurück zum Zitat Sastre J, Puente J, García-Saenz JA et al (2008) Irinotecan in the treatment of elderly patients with advanced colorectal cancer. Crit Rev Oncol Hematol 68:250–255CrossRefPubMed Sastre J, Puente J, García-Saenz JA et al (2008) Irinotecan in the treatment of elderly patients with advanced colorectal cancer. Crit Rev Oncol Hematol 68:250–255CrossRefPubMed
37.
Zurück zum Zitat Schiergens TS, Lindenthaler A, Thomas MN et al (2016) Time-dependent impact of age and comorbidities on long-term overall survival after liver resection. Liver Int 36:1340–1350CrossRefPubMed Schiergens TS, Lindenthaler A, Thomas MN et al (2016) Time-dependent impact of age and comorbidities on long-term overall survival after liver resection. Liver Int 36:1340–1350CrossRefPubMed
38.
Zurück zum Zitat Schlesinger-Raab A, Eckel R, Schubert-Fritschle G et al (2014) Survival benefit in colorectal cancer—an anlysis of a population-based clinical cancer registry. Oncol Res Treat 37(suppl 1):45 Schlesinger-Raab A, Eckel R, Schubert-Fritschle G et al (2014) Survival benefit in colorectal cancer—an anlysis of a population-based clinical cancer registry. Oncol Res Treat 37(suppl 1):45
39.
Zurück zum Zitat Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104–117CrossRefPubMed Siegel R, Desantis C, Jemal A (2014) Colorectal cancer statistics, 2014. CA Cancer J Clin 64:104–117CrossRefPubMed
40.
Zurück zum Zitat Tarantino I, Achermann P, Güller U, Ulrich A et al (2013) Relative survival is an adequate estimate of cancer-specific survival: baseline mortality-adjusted 10-year survival of 771 rectal cancer patients. Ann Surg Oncol 20(12):3877–3884 Tarantino I, Achermann P, Güller U, Ulrich A et al (2013) Relative survival is an adequate estimate of cancer-specific survival: baseline mortality-adjusted 10-year survival of 771 rectal cancer patients. Ann Surg Oncol 20(12):3877–3884
42.
Zurück zum Zitat Zacharias T, Jaeck D, Oussoultzoglou E et al (2004) First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg 240:858–865CrossRefPubMedPubMedCentral Zacharias T, Jaeck D, Oussoultzoglou E et al (2004) First and repeat resection of colorectal liver metastases in elderly patients. Ann Surg 240:858–865CrossRefPubMedPubMedCentral
Metadaten
Titel
Synchronous colorectal liver metastases: focus on the elderly
An Effectiveness Study from Routine Care
verfasst von
Markus Albertsmeier
Andrea Engel
Markus O. Guba
Sebastian Stintzing
Tobias S. Schiergens
Gabriele Schubert-Fritschle
Dieter Hölzel
Jens Werner
Martin K. Angele
Jutta Engel
Publikationsdatum
12.08.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 8/2017
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-017-1611-8

Weitere Artikel der Ausgabe 8/2017

Langenbeck's Archives of Surgery 8/2017 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.